Ultrahigh Specific Strength by Bayesian Optimization of Carbon Nanolattices.

Nanoarchitected materials are at the frontier of metamaterial design and have set the benchmark for mechanical performance in several contemporary applications. However, traditional nanoarchitected designs with conventional topologies exhibit poor stress distributions and induce premature nodal failure. Here, using multi-objective Bayesian optimization and two-photon polymerization, optimized carbon nanolattices with an exceptional specific strength of 2.

Comparing to three other enteric pathogens in OligoMM mice reveals pathogen-specific host and microbiota responses.

, non-typhoidal spp., and enteropathogenic/enterohemorrhagic (EPEC/EHEC) are leading causes of food-borne illness worldwide. has been used to model EPEC and EHEC infection in mice.

Transfemoral Compared to Transapical Transcatheter Aortic Valve Implantation in Chronic Dialysis-Dependent Patients.

Patients with end-stage kidney disease (ESRD) represent a high-risk population in terms of both development of and death by cardiovascular diseases. Outcome data of ESRD patients with severe aortic valve stenosis (AS) treated by transcatheter aortic valve implantation (AVI) are scarce. We aim to compare the outcome of ESRD patients undergoing transfemoral (TF) or transapical (TA) AVI.

Clinical Outcomes After Mitral Valve Replacement With Epic and Mosaic Bioprosthetic Valves.

Background: Comparative studies of outcomes between different biological mitral valve prostheses are scarce. This study compares the late clinical results of valve replacement with the Epic and Mosaic bioprostheses.

Methods: Patients undergoing isolated elective mitral valve replacement (MVR) between 2005 and 2019 were eligible for inclusion.

Mitral valve replacement versus repair for severe mitral regurgitation in patients with reduced left ventricular ejection fraction.

Objective: This study compares early and long-term outcomes following mitral valve (MV) repair and replacement in patients with mitral regurgitation (MR) and reduced left ventricular ejection fraction (LVEF).

Methods: Patients with primary or secondary MR and LVEF <50% who underwent MV replacement or repair (with/without atrial septal defect closure and/or atrial fibrillation ablation) between 2005 and 2017 at our center were retrospectively analyzed using unadjusted and propensity score matching techniques (42 pairs).

Results: A total of 356 patients with either primary (n = 162 [45.